Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial.

ABSTRACT: In oncology, the conventional reliance on the maximum tolerated dose (MTD) strategy for chemotherapy may not optimize treatment outcomes for individual patients. CURATE.AI is an AI-derived platform that utilizes a patient's own, small dataset to dynamically personalize only their own dose recommendations. The primary objective of this feasibility trial was to assess the logistical and scientific feasibility of providing dynamically personalized AI-derived chemotherapy dose recommendations for patients with advanced solid tumors at/for treatment with single-agent capecitabine, capecitabine in combination with oxaliplatin (XELOX), or capecitabine in combination with irinotecan (XELIRI). CURATE.AI demonstrated adaptability to clinically relevant situations encountered by patients often treate

SUBMITTER: Blasiak A 

PROVIDER: S-EPMC11845749 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature